2004-2008, Quantum Laboratories, Inc.. All rights reserved.



Major depressive disorders with psychotic features

Protocol C-1073-07 A Randomized, Double Blind , Placebo-Controlled Study of Safety and efficacy of C-1073 (Mifepristone) in the acute treatment of Major Depressive Disorder with Psychotic Features.

For more information please call (561) 687-2111



Our facility identifies and recruits appropriate patients and monitors them during the study. If you qualify and consent to participate, there will be no charge for your study medication and office visits. Additionally, you are responsible for attendence to regular scheduled appointments.


During any one-year period, up to 50 million Americans suffer from clearly diagnosable mental disorder involving a degree of incapacity that interferes with employment, attendence at school or daily life.